Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility
- 1 January 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (2) , 443-446
- https://doi.org/10.1016/j.bmcl.2005.09.053
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Dopamine D3 Receptor Partial Agonists and Antagonists as Potential Drug Abuse Therapeutic AgentsJournal of Medicinal Chemistry, 2005
- Enantiomerically Pure Hexahydropyrazinoquinolines as Potent and Selective Dopamine 3 Subtype Receptor LigandsJournal of Medicinal Chemistry, 2005
- Design, synthesis and structure–activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligandsBioorganic & Medicinal Chemistry Letters, 2005
- N-(ω-(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2 and D3 Receptor LigandsJournal of Medicinal Chemistry, 2003
- Structure−Affinity Relationship Study on N-[4-(4-Arylpiperazin-1-yl)butyl]arylcarboxamides as Potent and Selective Dopamine D3 Receptor LigandsJournal of Medicinal Chemistry, 2002
- Interactive SAR Studies: Rational Discovery of Super-Potent and Highly Selective Dopamine D3 Receptor Antagonists and Partial AgonistsJournal of Medicinal Chemistry, 2002
- Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugsPharmacology & Therapeutics, 2001
- Cocaine addiction therapy—Are we partially there?Nature Medicine, 1999
- Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonistNature, 1999
- Restless legs syndrome improved by pramipexoleNeurology, 1999